ucts, its dependence on collaborators for services and revenue, its
substantial indebtedness and lease obligations, its changing requirements
and costs associated with facilities, intense competition, the uncertainty
of patent and intellectual property protection, the Company's dependence on
key management and key suppliers, the uncertainty of regulation of
products, the impact of future alliances or transactions and other risks
described in the Company's filings with the Securities and Exchange
Commission. In addition, the Company will continue to face risks related to
animal and human testing, to the manufacture of ABthrax and to FDA
concurrence that ABthrax meets the requirements of the ABthrax contract. If
the Company is unable to meet the product requirements associated with the
ABthrax contract, the U.S. government will not be required to reimburse the
Company for the costs incurred or to purchase any ABthrax doses. Existing
and prospective investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of today's date.
Human Genome Sciences undertakes no obligation to update or revise the
information contained in this announcement whether as a result of new
information, future events or circumstances or otherwise.
'/>"/>SOURCE Human Genome Sciences, Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 Related biology technology :1.
Human Primary Preadipocytes and Differentiated Adipocytes2.
Low Abundance cDNA Cloned Using Stratagenes Human Universal
cDNA Library3.
Control RT-PCR Primers for Human Gene Transcripts with Varying Abundance4.
New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence
Humanized Renilla GFP Reporter5.
Human Universal cDNA Library Array I6.
Map and Link Human Genetic Disorders with SSLP Analysis7.
RT-PCR Primer Sets for Human and Mouse Mismatch Repair Genes8.
Transfection of Green Fluorescent Protein into Human Adrenalcarcinoma Cells9.
Fluorescence-Based Single-Tube Assays to Rapidly Detect Human Gene Mutations10.
Improve Lipid- or Calcium Phosphate-Mediated Transfection of Human Dermal
Fibroblasts11.
Sequence-Validated and Expression-Tested Human cDNA in a Dual Expression
Vector